Key Highlights
- Hydralyte LLC recorded an operating loss of US$66,900 for the September 2026 quarter, down 85% on the prior-year quarter.
- The Business recorded its first monthly operating profit of US$4,300 in August 2026.
- Revenue was US$665,200, down 22% on the prior corresponding period, with September affected by retail stock-outs.
- Cash stood at US$173,400 at 30 September 2026, and a pro-rata rights issue was announced in October.
The Hydration Pharmaceuticals Company Limited (ASX:HPC) released its quarterly activities report and Appendix 4C on 30 October 2026, covering the three months ended 30 September 2026. The company's trading activity is conducted through Hydralyte LLC, its wholly owned US subsidiary, which sells Hydralyte products through Amazon, retail pharmacies and direct-to-consumer channels. The report sets out the subsidiary's operating results, cost reductions and the funding plan announced in October.
Operating Results
Hydralyte LLC recorded Revenue of US$665,200 for the quarter, a decline of 22% on the prior corresponding period. The company said September was affected by stock-outs in the retail channel, which have since been rectified, and that the underlying decline excluding those lost retail sales was about 15%. Gross Margin was 65%, compared with 66% a year earlier, and reached 73% in August.
The operating loss was US$66,900, compared with US$446,500 in the prior corresponding quarter. Net loss after tax was US$35,700, down 92%, after other income of US$31,100 recognised in September. The company also reported a maiden monthly operating profit of US$4,300 in August 2026, on revenue of US$234,000.
The company's report explains that a stock-out in the retail channel in September affected revenue for that month. The company said the retail stock position has since been rectified, and it allocated part of the quarter's Cash Flow to inventory and packaging payments to restore availability for the December quarter.
Cost Base and Advertising Spend
Total operating expenses fell 58% to US$313,900. Operating costs excluding advertising declined 62% to US$143,400, or about US$48,000 per month, against about US$124,000 per month a year earlier. Advertising and Marketing spend was cut 54% to US$170,600, equal to 26% of revenue, compared with 44% in the prior corresponding quarter. Revenue per advertising dollar rose to US$3.90 from US$2.28.
The company's advertising spend figures show that advertising and marketing costs fell faster than revenue in the period. The report presents revenue per advertising dollar as a measure of return, and the figure rose to US$3.90 from US$2.28 in the prior corresponding quarter.
Cash Flow and Funding Plan
Net operating cash outflow decreased 27% to US$249,500, compared with US$343,500 in the June quarter. The outflow included US$158,600 of payments for inventory and packaging to restore stock availability for the December quarter, and US$50,000 of settlements of prior-period invoices. Cash was US$173,400 at 30 September 2026. The company announced a pro-rata rights issue in October to fund the business through to sustainable profitability.
Sector Context and Risks to Watch
Consumer products sold through online marketplaces and retail pharmacies face inventory cycles, promotional costs and competition from other rehydration and electrolyte brands. The company's report reflects these pressures through its stock-outs, its advertising reductions and its restocking payments during the quarter.
The risks the company's figures point to are continuing revenue decline on a year-on-year basis, the dependence on the December quarter restocking and the completion of the rights issue. The company said the rights issue is intended to fund the business through to sustainable profitability, so shareholders will be watching the terms of the offer and whether the operating profit recorded in August is repeated in later months.
Final Word
The quarter shows a lower loss, a lower cost base and a first monthly operating profit, alongside a fall in revenue and a continuing operating cash outflow. The December quarter will show whether the company keeps its advertising spend at current levels and how its restocking affects cash, while the rights issue sets out the funding path the company has chosen.






Please wait processing your request...